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Tandem cycles of high-dose chemotherapy are an increasingly being used as alternative to radiation treat-
ment in the management of infants and young children with central nervous system (CNS) tumors. Most of
these protocols have a carboplatinum and thiotepa backbone. The toxicities of these regimens have been
reported extensively; however, pulmonary arterial vasculopathy (PAV) with pulmonary arterial hypertension
(PAH) has not been previously documented in patients treated with this approach. PAH is a disorder of the
pulmonary vasculature characterized by a progressive increase in pulmonary vascular resistance, leading to
right heart failure and potentially death. We evaluated PAH as a complication after high-dose chemotherapy
and autologous stem cell transplantation (SCT). We performed a retrospective evaluation of all pediatric
patients diagnosed with a CNS tumor between 2001 and 2010 scheduled to receive 3 cycles of high-dose
chemotherapy with carboplatinum (17 mg/kd/day for 2 days) and thiotepa (10 mg/kg/day for 2 days), fol-
lowed by autologous SCT. Our primary objective was to evaluate the incidence of PAV and PAH in this pop-
ulation, as well as patient outcomes after the development of PAH. Our cohort comprised 20 patients with
a median age at diagnosis of 28 months (range, 3-131 months). Three patients developed biopsy-conﬁrmed
PAV with PAH, the 2 patients who developed PAV with PAH at the end of the third cycle succumbed to PAH.
Death due to PAV and PAH was the sole toxic mortality observed during the study period. PAV with PAH is
a major and possibly fatal complication after high-dose chemotherapy and sequential autologous SCT using
carboplatinum and thiotepa in a tandem fashion. There is an urgent need to evaluate PAH as a potential
complication after each cycle of high-dose chemotherapy when using such regimens in pediatric patients
with CNS tumors.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION pilot tested with success, and this modality is an increasingly
Central nervous system (CNS) tumors constitute the most
common solid tumors in children [1]. Current treatment
recommendations for malignant CNS tumors include
maximal surgical resection, followed by focal or craniospinal
irradiation and/ormultiagent chemotherapy [2-4]. The use of
large-ﬁeld irradiation, particularly craniospinal irradiation,
in young children and infants carries risks of severe cognitive
deﬁcit, hormonal imbalance, and impaired growth [5-7]. In
an attempt to improve survival rates and reduce radiation-
related morbidity, high-dose chemotherapy with autolo-
gous stem cell transplantation (SCT) has been advocated for
young children and infants with malignant CNS tumors [8,9].
There is growing evidence indicating that high-dose
chemotherapy followed by autologous SCT has a role in
ﬁrst-line treatment in selected infants and young children
with CNS tumors [4,10-12]. Tandem high-dose chemo-
therapy regimens followed by autologous SCT have beendgment on page 238.
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The toxicity of high-dose chemotherapy regimens in
patients with CNS tumors is well documented [14-17], and
increasing awareness has contributed to a signiﬁcant
reduction inmortality rates. Other toxicities have not been as
well described, however. Here we report the risk for the
development of pulmonary arterial hypertension (PAH) after
tandem high-dose chemotherapy with carboplatinum and
thiotepa in young childrenwith CNS tumors. PAH is a serious
disorder of the pulmonary vasculature, characterized by
a progressive increase in pulmonary vascular resistance,
eventually leading to right heart failure and death.
PATIENTS AND METHODS
With Institutional Review Board approval, we reviewed the records of
all patients diagnosed with a primary CNS tumor at The Hospital for Sick
Children between 2001 and 2010 who were scheduled to receive tandem
cycles of high-dose chemotherapy followed by autologous SCT. Data
collected included demographic characteristics, diagnosis, initial manage-
ment, high-dose chemotherapy regimen, pulmonary complications of high-
dose chemotherapy, and outcomes.
Patients underwent tumor resection (17 patients) or biopsy (3 patients)
followed by intensive chemotherapy. They all had peripheral blood stem
cells mobilized with granulocyte colony-stimulating factor at the end of the




Atypical teratoid rhabdoid tumor 8
Medulloblastoma 4
Primitive neuroectodermal tumor 2
High-grade glioma 3
Choroid plexus carcinoma 2
CNS sarcoma 1
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All 20 patients were scheduled to receive 3 courses of tandem high-dose
chemotherapy with a carboplatinum-thiotepa conditioning regimen, fol-
lowed by autologous SCT 21 days later. The planned carboplatinum dosewas
17 mg/kg/day for 2 days given concurrently with thiotepa 10 mg/kg/day for
2 days, on days -3 and -2 before stem cell infusion. The day of stem cell
infusion was deﬁned as day 0. Before each cycle, echocardiography was
performed, oxygen saturation assessed, and any respiratory or cardiac
complications were documented. After autologous SCT, patients were iso-
lated until engraftment.
PAH
Criteria for diagnosing PAH were based on European Society of Cardi-
ology/European Respiratory Society guidelines [18]. PAH is a clinical diag-
nosis characterized by precapillary pulmonary hypertension. It includes
different forms that share a similar clinical picture and identical pathological
changes of the lung [18]. In patients who developed PAH, echocardiography,
imaging, and biopsy results were documented. PAH outcome and survival
were recorded.
Lung Biopsy Tissue Processing
Lung biopsy specimens were obtained from the middle or lower lobe of
the right lung and processed in accordance with a recommended protocol
for handling pediatric lung biopsy specimens [19]. For light microscopy
examination, tissue was ﬁxed in 10% buffered formalin and embedded in
parafﬁn. In addition to routine hematoxylin and eosin staining, special stains
(ie, elastic trichrome stain) to demonstrate pulmonary vasculature and
stains to rule out infectious organisms (ie, Gram, Ziel Nielsen, and Steiner for
bacteria and periodic acid-schiff and Gomori (PAS) and methenamine silver
(GMS) for fungi) were performed on all 3 biopsy specimens. To rule out viral
infection, immunostaining for adenovirus, respiratory syntitial virus, and
cytomegalovirus were performed following established immunohisto-
chemistry protocols. Electron microscopy (EM) examination was performed
following standard protocols.
RESULTS
During the study period, 20 patients (11 males, 9 females)
with a CNS tumor were treated with 3 cycles of high-dose
carboplatinum and thiotepa as part of their conditioning
regimen. The median age at time of diagnosis was 28months
(range, 3-131 months). Patient diagnoses are summarized in
Table 1. After diagnosis, all but 3 patients underwent surgery
aimed at total resection, and 3 patients underwent biopsy.
The backbone of the induction chemotherapy given to 18
patients was a combination of vincristine, etoposide, cyclo-
phosphamide, and cisplatinum. Three patients also received
intrathecal methotrexate.
All patients had normal echocardiography ﬁndings with
an ejection fraction of >55% and a shortening fraction of
>30% before each cycle of chemotherapy. Oxygen saturation
was >95% in room air before each cycle.
Three patients developed noninfectious respiratory
complications. Patient 1, a 3-month-old male infant, was
diagnosed with a nonmetastatic (M0) atypical teratoid
rhabdoid tumor of the right lateral ventricle. He underwent
near-total resection of his primary tumor. His postoperative
staging was negative for metastatic disease. He received
chemotherapy with i.v. methotrexate, vincristine, etoposide,
cyclophosphamide, and cisplatin. Echocardiography and
oxygen saturation results were normal before the 2 cycles ofhigh-dose chemotherapy. At 7 days after a second stem cell
infusion, he presented with tachypnea and desaturation
episodes necessitating oxygen supplementation. Chest radi-
ography revealed increased heart size and mild central
vascular and interstitial prominence. Echocardiography
showed a dilated right ventricle (RV) with severe decreased
RV systolic function, with an RV systolic pressure (RVSP) of
95 mmHg. Lung biopsy analysis conﬁrmed the diagnosis
of PAV.
Further chemotherapy was not given once PAH was
diagnosed. Oxygen support was provided for 8 months, and
RVSP gradually improved. Echocardiography performed 3
months after the diagnosis of PAH revealed an RVSP of 31
mmHg. The patient developed disseminated recurrence 8
months after completing therapy and died of disease
progression at age 21 months.
Patient 2 was a 4-month-old baby girl diagnosed with
metastatic (M2) atypical teratoid rhabdoid tumor in the
posterior fossa. She underwent total resection of her primary
tumor in the posterior fossa and partial resection of a meta-
static deposit in the supratentorial region. After induction
chemotherapy with i.v. methotrexate, vincristine, etoposide,
cyclophosphamide, and cisplatin, she was treated with 3
cycles of high-dose chemotherapy and autologous SCT. At
day þ5 after the third stem cell infusion, she developed
tachypnea and tachycardia. Echocardiography showed
severely reduced RV function and an RVSP of 96mmHg. Lung
biopsy conﬁrmed the diagnosis of PAV.
The patient required intubation and mechanical ventila-
tion. She was treated with nitric oxide (NO) and high-dose
steroids. Before NO treatment, her RVSP was 130 mmHg
(systemic pressure, 75 mmHg). After NO treatment, only
minimal changes were seen in RVSP (100 mmHg) for
a systemic pressure of 88 mmHg. Despite symptomatic
management, she died on day þ26 after the third cycle from
PAH.
Patient 3, a 32-month-old boy with nonmetastatic classic
posterior fossa medulloblastoma, underwent total resection
of his primary tumor. After induction chemotherapy with i.v.
vincristine, etoposide, cyclophosphamide, and cisplatinum,
he was treated with 3 cycles of high-dose carboplatinum and
thiotepa without complications. He developed respiratory
distress and required oxygen on day 0 of his third cycle of
high-dose chemotherapy. Chest radiography revealed bilat-
eral increased interstitial markings. Analysis of bron-
choalveolar lavage ﬂuid was negative for infection.
Echocardiography showed normal heart function, with an
RVSP of 44 mmHg and dilation of the RV and right atrium.
Lung biopsy analysis documented PAV. RVSP increased to 81
mmHg with a temporary response to NO. Despite treatment,
the patient developed congestive heart failure, and he died of
PAH and congestive heart failure on day þ18.
At 3 years post-SCT, the entire cohort had an overall
survival of 0.55  0.11, progression-free survival of 0.66 
0.11, and nonrelapse mortality of 0.15  0.09.
Lung Biopsy Findings
The 3 patients had similar pathology ﬁndings on analysis
of lung biopsy specimens. Overall, the lung parenchyma was
preserved, and the airways and alveolar compartment
appeared near normal or showed mild intestinal thickening
owing to edema and early ﬁbrosis, but no evidence of
inﬂammatory inﬁltrate (Figures 1 and 2). All special stains
and immunostains for infectious organisms were negative.
The primary abnormality was marked diffuse thickening of
Figure 1. Lung biopsy specimen from patient 1 showing well-expanded and
relatively well-preserved alveolar spaces (Alv). Three small preacinar pulmo-
nary arteries (PA) show striking luminal narrowing. The pulmonary vein (PV)
shows no abnormalities. (Elastic trichrome stain; scale bar: 500 m.)
Figure 3. Electron micrograph of alveolar capillary membrane in a lung biopsy
specimen from patient 2. The alveolus is lined by cytoplasm of alveolar type 2
cells (Type II) containing osmiophilic lamellar bodies. The alveolar capillary
loop shows markedly thickened cytoplasm of endothelial cells (End). The
lumen contains RBCs. The alveolar capillary basement membrane is indicated
by an arrow; the thin process of alveolar type 1 cells covering alveolar capil-
laries is indicated by double arrows. (Scale bar: 2 m.)
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hyperplasia with concentric luminal narrowing highlighted
on elastic trichrome staining (Figures 1 and 2). No evidence
of vasculitis or thrombosis was seen. Pulmonary veins and
lymphatics were unaffected. EM examination revealed mild
type 2 cell hyperplasia with focal enlargement of lamellar
bodies, suggestive of drug effects. The cytoplasm of endo-
thelial cells lining the alveolar capillaries forming the
aireblood barrier, which is normally very thin (<2 m),
demonstrated increased thickness (2- to 3-fold greater than
normal) and focal swelling consistent with endothelial cell
injury (Figure 3). This change also might account for the
reduced gas exchange. In addition, aggregates of ﬁbrin were
evident in the lumen of some capillaries, suggestive of
intravascular coagulation (not shown).Figure 2. Lung biopsy specimen from patient 2 showing focal thickening of
the interstitium (asterisk) and obliterative changes affecting small pulmonary
artery (PA) branches, with normal-appearing pulmonary veins (PV). (Elastic
trichrome stain; scale bar: 500 m.) (Inset) Higher-magniﬁcation view of
a pulmonary arteriole showing marked ﬁbrointimal thickening and pinpoint
lumen. Media is delineated by elastic laminae (black). (Elastic trichrome stain;
scale bar: 50 m.)DISCUSSION
Here we report PAV and PAH as common and potentially
fatal complications of sequential cycles of high-dose
chemotherapy and stem cell rescue using a high-dose car-
boplatinumethiotepa combination in infants and young
children with CNS tumors. Occlusive PAV is a rare compli-
cation of high-dose chemotherapy followed by SCT [19]. The
pathological changes of concentric narrowing of small
pulmonary arteries due to ﬁbrointimal hyperplasia seen in
our 3 patients are similar to those reported previously
[20,21,22]; however, no ultrastructural studies of such cases
have been reported to date. The superior resolution of EM
allows examination of lung components such as the alveolar
capillary membrane and its lining cells. In the present study,
we have identiﬁed ultrastructural changes pointing to alve-
olar capillary endothelium and epithelial cells as potential
targets of drug toxicity, although the precise mechanism is
unknown.
CNS tumors in early childhood are associated with poor
outcome owing to their aggressive biological behavior, as
well as to the avoidance or deferral of radiation therapy
common in this age group [23]. The use of sequential mye-
loablative high-dose chemotherapy for speciﬁc CNS tumors
has demonstrated efﬁcacy and improved survival, and is
currently considered an acceptable approach [9,16,24,25].
Previous studies of pediatric primary CNS tumors using such
protocols did not identify PAV and PAH as potential compli-
cations [19,25-27]; however, pulmonary complications are
common causes of toxicity in patients with CNS tumors
treated with high-dose chemotherapy and SCT. Finlay et al.
[28] reported a patient who died from respiratory failure of
unknown etiology at 4 months after a second SCT and
therapy with thiotepa 600mg/m2. Gilman et al. [12] reported
a 44% pulmonary toxicity rate in 32 children with recurrent
brain tumors treated in a phase 1 study of sequential high-
dose chemotherapy and stem cell rescue. The conditioning
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mustine 300 mg/m2, followed by thiotepa 600 mg/m2 and
carboplatinum 1200 mg/m2. Of the 8 patients who died,
6 had pulmonary failure, including 2 with a documented
diagnosis of PAH. The prevalence of PAH in this cohort was
presumably higher, given that noninfectious pulmonary
complications responded to steroid therapy [12].
To date, PAV and PAH have been implicated only rarely as
complications of allogeneic and autologous SCT. Only a few
case reports of PAH after allogeneic SCT have been published
[21,28,29]. More than 2 decades ago, Hackman et al. [30]
described PAH in 2 children after high-dose BCNU (carmus-
tine) and radiation therapy. Seguchi et al. [29] reported PAH
in a 20-year-old man, which developed 3 months after
receipt of a conditioning regimen comprising cyclophos-
phamide, total body irradiation, and cytarabine. Vaksmann
et al. [21] reported a case of PAH in an 8-year-old girl
developing 5 months after allogeneic SCT with a condi-
tioning regimen of cyclophosphamide, busulfan, and cytar-
abine. Similar to our ﬁndings, previous lung biopsy analyses
have shown partial to complete occlusion of small pulmo-
nary arteries by ﬁbrous proliferation of the intima [21,30].
Although early-onset PAH has been attributed to direct
damage from chemotherapy, previous conditioning regi-
mens did not include thiotepa or carboplatinum [30].
Another potential cause of PAH in patients after allogeneic
SCT is graft-versus-host disease (GVHD). Grigg et al. [31]
reported late-onset PAH as an unusual manifestation of
chronic GVHD, with microvascular damage mediated by
cytokines. This complication is rare in the context of GVHD
but is not relevant to our patient population, given that all of
our patients underwent autologous SCT.
Interestingly, PAH is a common and serious complication
after allogeneic SCT in infants with malignant infantile
osteopetrosis. The reported incidence of PAH in this context
is 29%. The mechanism of PAH in these patients is unknown;
it is possible that an idiosyncratic drug reaction restricted to
patients withmalignant infantile osteopetrosis is responsible
for the high incidence [31]. Similar to infants with osteo-
petrosis, the youngest 2 patients in our study developed PAH,
suggesting that infants with CNS tumors treated with high-
dose chemotherapy are at greater risk for PAH.
The differential diagnosis for PAH includes hypertension
caused by pulmonary veno-occlusive disease (PVOD), an
increasingly recognized complication after SCT [22]. A high
prevalence of PVOD has been documented in infants with
osteopetrosis after allogeneic SCT [31]. Malhotra et al. [32]
reported PVOD as a cause of reversible PAH in a patient
with multiple myeloma undergoing autologous SCT.
Trobaugh-Lotrario et al. [33] reported a case of fatal PVOD
after autologous SCT in a child with stage IV neuroblastoma.
Biopsy analysis usually conﬁrms the diagnosis of PVOD. Most
of the patients also had secondary arteriolar medial hyper-
trophy and intimal proliferation [33].
Potential therapies for PAH in our population include
vasodilators, such as NO. Our patients demonstratedminimal
or no response to NO. Similarly, high-dose corticosteroids
(20 mg/kg/day i.v. methylprednisolone for 3 days, followed
by tapering) were used. High-dose corticosteroid therapy has
been reported effective in managing patients with PVOD
[34]. None of our patients had a documented response to
corticosteroids. Other potential therapies for PAV and PAH in
patients receiving cytotoxic drugs may be derived from
studies using experimental models of drug-induced PAH,
including a model of monocrotaline (MCT)-induced lunginjury in rats that mimics many features of human pulmo-
nary hypertensive arteriopathy [35]. For example, a recent
study found that pretreatment with the synthetic activator
of angiotensin-converting enzyme 2, a member of the vas-
oprotective axis, prevented the development of PAV and PAH
in rats receiving MCT [36]. Various other drugs and
compounds also have been shown to negate the effects of
MCT and to prevent and/or reverse the development of
pulmonary hypertensive arteriopathy [35].
In summary, PAH is a common complication after tandem
high-dose chemotherapy with thiotepa and carboplatinum
followed by autologous SCT in young patients with CNS
tumors. This potentially fatal toxicity should be considered
and investigated in pediatric patients who develop respira-
tory symptoms after receiving this combination therapy,
particularly in a sequential manner. Early diagnosis might
improve outcomes. This complication should be critically
appraised when consideration for future studies is per-
formed. When tandem cycles are considered appropriate,
echocardiography should be performed between cycles, with
a particular focus on RV pressure. Guidelines for further
therapy should be developed to help prevent this fatal
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